PARP inhibitors and stratified treatment of prostate cancer

被引：5
|
作者：
Lavery, Anita [1 ]
Gilson, Clare [2 ]
Chowdhury, Simon [3 ]
机构：
[1] Guys Hosp, Med Oncol, London, England
[2] UCL, MRC Clin Trials Unit, London, England
[3] Guys Hosp, London, England
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 12期
关键词：
Biomarker; BRCA1/2; mutation; PARP inhibitor; prostate cancer; stratification; targeted therapy; HOMOLOGOUS RECOMBINATION; INCREASED SURVIVAL; REPAIR DEFECTS; RESISTANCE; BIOMARKERS; BRCA2;
D O I：
10.1080/14737140.2016.1243474
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1213 / 1215
页数：3
相关论文
共 50 条
  • [31] Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto, Naohiro
    Harada, Kenichi
    Shiota, Masaki
    Tomisaki, Ikko
    Minato, Akinori
    Nagata, Yujiro
    Kimuro, Rieko
    Harada, Mirii
    Fujisawa, Masato
    [J]. ANTICANCER RESEARCH, 2021, 41 (10) : 4687 - 4695
  • [32] Non-NAD-like PARP-1 inhibitors in prostate cancer treatment
    Karpova, Yaroslava
    Wu, Chao
    Divan, Ali
    McDonnell, Mark E.
    Hewlett, Elizabeth
    Makhov, Peter
    Gordon, John
    Ye, Min
    Reitz, Allen B.
    Childers, Wayne E.
    Skorski, Tomasz
    Kolenko, Vladimir
    Tulin, Alexei V.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2019, 167 : 149 - 162
  • [33] The growing role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer
    Panzone, John
    Rood, Gavrielle J.
    Goldberg, Hanan
    [J]. TRANSLATIONAL CANCER RESEARCH, 2023, 12 (12) : 3233 - 3240
  • [34] Combination treatment of PARP and SRC inhibitors in BRCA2 mutated prostate cancer
    Khan, Nabeela
    Chakraborty, Goutam
    Nandakumar, Subhiksha
    Mazzu, Ying Z.
    Atiq, Mohammad
    Yoshikawa, Yuki
    Lee, Gwo-Shu Mary
    Kantoff, Philip
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [35] Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Jang, Albert
    Sartor, Oliver
    Barata, Pedro C.
    Paller, Channing J.
    [J]. CANCERS, 2020, 12 (11) : 1 - 14
  • [36] PARP inhibitors: its role in treatment of cancer
    Alice Chen
    [J]. 癌症, 2011, 30 (07) : 463 - 471
  • [37] PARP inhibitors as precision medicine for cancer treatment
    Du, Yi
    Yamaguchi, Hirohito
    Hsu, Jennifer L.
    Hung, Mien-Chie
    [J]. NATIONAL SCIENCE REVIEW, 2017, 4 (04) : 576 - 592
  • [38] PARP Inhibitors for Breast Cancer Treatment A Review
    Morganti, Stefania
    Marra, Antonio
    De Angelis, Carmine
    Toss, Angela
    Licata, Luca
    Giugliano, Federica
    Taurelli Salimbeni, Beatrice
    Berton Giachetti, Pier Paolo Maria
    Esposito, Angela
    Giordano, Antonio
    Bianchini, Giampaolo
    Garber, Judy E.
    Curigliano, Giuseppe
    Lynce, Filipa
    Criscitiello, Carmen
    [J]. JAMA ONCOLOGY, 2024, 10 (05) : 658 - 670
  • [39] Advances in PARP inhibitors for the treatment of breast cancer
    Dizdar, Omer
    Arslan, Cagatay
    Altundag, Kadri
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2751 - 2758
  • [40] PARP inhibitors in the treatment of ovarian cancer: a review
    Washington, Christina R.
    Moore, Kathleen N.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 1 - 6
12345